Bumpy road to broad availability of biosimilars
Biosimilar drugs, which could have provided cost relief to the nation’s health care system as early as this year, have been delayed, putting more pressure on patients and payers as the demand for specialty medications is projected to climb by double digits through the end of the decade, according to